Travere Therapeutics to Present Abstracts on FILSPARI (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association

Upcoming data presentations underscore the potential for FILSPARI to become a foundational treatment for IgAN and Travere’s leadership and commitment to innovation in rare kidney disease (RKD)

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present nine abstracts in rare kidney disease at the World Congress of Nephrology (WCN) in Buenos Aires, Argentina, on April 13-16, 2024, and the American Nephrology Nurses Association (ANNA) National Symposium in Orlando, Florida, on April 14-17, 2024.

At WCN, the Company will present subgroup analyses of the Phase 3 PROTECT Study of FILSPARI (sparsentan) in IgA nephropathy (IgAN) showing the treatment effect across participants with different levels of baseline proteinuria. Encore presentations will include preliminary findings from the SPARTAN Study supportive of FILSPARI as a first-line treatment for patients with IgAN, as well as the early clinical experience from the PROTECT open-label extension regarding the addition of sodium-glucose cotransporter-2 inhibitors (SGLT2i) to ongoing FILSPARI treatment in patients with IgAN. At ANNA, the Company will present additional insights from the HONUS trial, including health-related quality of life (HRQoL) data and the humanistic burden experienced by patients with IgAN and focal segmental glomerulosclerosis (FSGS).

“The data we are presenting at WCN and ANNA reinforce the wealth of evidence supporting FILSPARI’s profile to become an effective foundational treatment replacing RAAS inhibition, with the potential to reduce the lifetime risk of kidney failure for patients with IgAN,” said Jula Inrig, M.D., chief medical officer of Travere Therapeutics. “We are also looking forward to presenting data that address broader aspects of disease management, building upon Travere’s holistic approach to improving patient outcomes in RKD.”

WCN Late Breaking Abstract

Sparsentan vs Irbesartan in Patients with Immunoglobulin A Nephropathy (IgAN): Subgroup Analyses of 2-Year Results from the Pivotal Phase 3 PROTECT Trial
Oral Presentation: MON-296
Late Breaking Clinical Trial Session
Exhibition Hall and Main Foyer; April 15, 2024, 3:35-3:45 p.m. ART

WCN Poster Presentations

Sparsentan as First-Line Treatment of Incident Patients with IgA Nephropathy: Preliminary Findings from the SPARTAN Trial
Poster: SUN-042
Poster Session: Clinical Glomerulonephritis 2
Exhibition Hall and Main Foyer; April 14, 2024, 5:45-6:45 p.m. ART

Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)